Cellectis S.A.

Developing allogeneic CAR T-cell cancer immunotherapies using TALEN® gene-editing technology.

CLLS | NDAQ

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: 8 RUE DE LA CROIX JARRY, 0 PARIS, LLE-DE-FRANCE
Website:: https://www.cellectis.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cellectis S.A. is a clinical-stage biopharmaceutical company specializing in the development of cancer immunotherapies. The company leverages its proprietary gene-editing technology, TALEN®, to engineer Chimeric Antigen Receptor (CAR) T-cells. Cellectis focuses on creating allogeneic, or "off-the-shelf," CAR T-cell product candidates from healthy donor cells. This approach aims to provide broadly available and scalable treatments for a large number of patients, in contrast to personalized autologous therapies. The company's technology is designed to solve key challenges in allogeneic cell therapy, including Graft-versus-Host Disease (GvHD) and host-versus-graft rejection. Cellectis maintains a strong intellectual property portfolio and collaborates with global strategic partners to advance its therapeutic pipeline.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Cellectis S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cellectis S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Cellectis S.A. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
AVADEL PHARMACEUTICALS PLC Develops once-at-bedtime therapies for adults with narcolepsy using innovative drug delivery.	United States of America	AVDL
Avidity Biosciences, Inc. Pioneering targeted RNA therapies that treat the root cause of rare muscle diseases.	United States of America	RNA
Axsome Therapeutics, Inc. Biopharma company developing novel therapies for central nervous system (CNS) conditions.	United States of America	AXSM
AYTU BIOPHARMA, INC Specialty pharma advancing innovative medicines for CNS diseases like MDD and ADHD.	United States of America	AYTU
Azitra, Inc. Developing engineered proteins and live biotherapeutics for rare skin diseases.	United States of America	AZTR
Bachem Holding AG A CDMO developing and manufacturing peptides and oligonucleotides for pharma and biotech.	Switzerland	BANB
Barinthus Biotherapeutics plc. Develops T cell immunotherapies for autoimmune and chronic infectious diseases.	United States of America	BRNS
Basilea Pharmaceutica AG Develops & commercializes anti-infectives for severe bacterial & fungal infections.	Switzerland	BSLN
Bausch Health Companies Inc. Develops, manufactures, and markets pharmaceuticals, OTCs, and medical devices globally.	United States of America	BHC
Bavarian Nordic A biotech firm developing and manufacturing life-saving vaccines for travel and public health.	Denmark	BAVA